T1	Premise 915 1136	For the chemotherapy group, the mean Quality Adjusted Life Months over 24 months (QALM-24) was 9.6 (95% CI: 8.7, 11.2) months compared with the mean QALM-24 of 8.6 (95% CI: 7.6, 10.5) months for the no chemotherapy group.
T2	Premise 1137 1315	For the chemoradiation group, the mean QALM-24 was 7.1 (95% CI: 6.0, 9.0) months compared with the mean QALM-24 of 8.1 (95% CI: 7.0, 10.0) months for the no chemoradiation group.
T3	Claim 1476 1622	Chemotherapy provided on average an additional 1.0 quality-adjusted life months within a restricted 2-year time period from the time of resection.
T4	Claim 1316 1475	The previously reported survival advantage supporting the use of adjuvant chemotherapy is maintained when adjusted using quality adjusted survival methodology.
R1	Support Arg1:T2 Arg2:T4	
R2	Support Arg1:T1 Arg2:T4	
R3	Support Arg1:T2 Arg2:T3	
R4	Support Arg1:T1 Arg2:T3	
